Literature DB >> 17805937

Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis.

Hari Nathan1, Timothy M Pawlik, Christopher L Wolfgang, Michael A Choti, John L Cameron, Richard D Schulick.   

Abstract

The prognosis of patients with cholangiocarcinoma historically has been poor, even after surgical resection. Although data from some single-institution series indicate improvement over historical results, survival after surgical therapy for cholangiocarcinoma has not been investigated in a population-based study. We used the Surveillance, Epidemiology, and End Results database to identify patients who underwent surgery for cholangiocarcinoma from 1973 through 2002. Multivariate modeling of survival after surgery for intrahepatic cholangiocarcinoma showed an improvement in survival only within the last decade studied, resulting in a cumulative 34.4% improvement in survival from 1992 through 2002. In contrast, multivariate modeling of survival after surgery for extrahepatic cholangiocarcinoma revealed a 23.3% increase in adjusted survival per each decade studied, resulting in a cumulative 53.7% improvement from 1973 through 2002. We conclude that survival after surgery for extrahepatic cholangiocarcinoma has dramatically improved since 1973. Patients with intrahepatic cholangiocarcinoma, however, have achieved an improvement in survival largely confined to more recent years. We suggest that these trends are largely caused by developments in imaging technology, improvements in patient selection, and advances in surgical techniques.

Entities:  

Mesh:

Year:  2007        PMID: 17805937     DOI: 10.1007/s11605-007-0282-0

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  39 in total

1.  One thousand consecutive pancreaticoduodenectomies.

Authors:  John L Cameron; Taylor S Riall; JoAnn Coleman; Kenneth A Belcher
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

Review 2.  Radiation therapy in the treatment of cholangiocarcinoma.

Authors:  Brian G Czito; Mitchell S Anscher; Christopher G Willett
Journal:  Oncology (Williston Park)       Date:  2006-07       Impact factor: 2.990

3.  Surgical management of hilar cholangiocarcinoma: the Nagoya experience.

Authors:  Hideki Nishio; Masato Nagino; Yuji Nimura
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

4.  Aggressive surgical approaches to hilar cholangiocarcinoma: hepatic or local resection?

Authors:  M Miyazaki; H Ito; K Nakagawa; S Ambiru; H Shimizu; Y Shimizu; A Kato; S Nakamura; H Omoto; N Nakajima; F Kimura; T Suwa
Journal:  Surgery       Date:  1998-02       Impact factor: 3.982

5.  Adenocarcinoma of the distal bile duct. A clinicopathologic outcome analysis after curative resection.

Authors:  L Bortolasi; L J Burgart; G G Tsiotos; E Luque-De León; M G Sarr
Journal:  Dig Surg       Date:  2000       Impact factor: 2.588

6.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

7.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

8.  Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival.

Authors:  H A Pitt; A Nakeeb; R A Abrams; J Coleman; S Piantadosi; C J Yeo; K D Lillemore; J L Cameron
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

9.  Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma.

Authors:  C H Su; S H Tsay; C C Wu; Y M Shyr; K L King; C H Lee; W Y Lui; T J Liu; F K P'eng
Journal:  Ann Surg       Date:  1996-04       Impact factor: 12.969

10.  Surgical treatment of cholangiocellular carcinoma.

Authors:  R Pichlmayr; P Lamesch; A Weimann; G Tusch; B Ringe
Journal:  World J Surg       Date:  1995 Jan-Feb       Impact factor: 3.352

View more
  97 in total

1.  Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis.

Authors:  Sarah B Fisher; Sameer H Patel; David A Kooby; Sharon Weber; Mark Bloomston; Clifford Cho; Ioannis Hatzaras; Carl Schmidt; Emily Winslow; Charles A Staley; Shishir K Maithel
Journal:  HPB (Oxford)       Date:  2012-05-22       Impact factor: 3.647

2.  Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins.

Authors:  Evan S Glazer; Ping Liu; Eddie K Abdalla; Jean-Nicolas Vauthey; Steven A Curley
Journal:  J Gastrointest Surg       Date:  2012-07-10       Impact factor: 3.452

Review 3.  Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

4.  Survival outcomes and prognostic factors of surgical therapy for all potentially resectable intrahepatic cholangiocarcinoma: a large single-center cohort study.

Authors:  Xianwu Luo; Lei Yuan; Yi Wang; Ruiliang Ge; Yanfu Sun; Gongtian Wei
Journal:  J Gastrointest Surg       Date:  2014-01-07       Impact factor: 3.452

5.  Intrahepatic cholangiocarcinoma: clinicopathological differences between peripheral type and hilar type.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Akira Nakashima; Taijiro Sueda
Journal:  J Gastrointest Surg       Date:  2011-10-20       Impact factor: 3.452

Review 6.  The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer.

Authors:  Hwajeong Lee; Jeffrey S Ross
Journal:  Therap Adv Gastroenterol       Date:  2017-03-28       Impact factor: 4.409

7.  The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma.

Authors:  Joon-Yong Chung; Seung-Mo Hong; Byeong Yeob Choi; Hyungjun Cho; Eunsil Yu; Stephen M Hewitt
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

8.  Recurrence after operative management of intrahepatic cholangiocarcinoma.

Authors:  Omar Hyder; Ioannis Hatzaras; Georgios C Sotiropoulos; Andreas Paul; Sorin Alexandrescu; Hugo Marques; Carlo Pulitano; Eduardo Barroso; Bryan M Clary; Luca Aldrighetti; Cristina R Ferrone; Andrew X Zhu; Todd W Bauer; Dustin M Walters; Ryan Groeschl; T Clark Gamblin; J Wallis Marsh; Kevin T Nguyen; Ryan Turley; Irinel Popescu; Catherine Hubert; Stephanie Meyer; Michael A Choti; Jean-Francois Gigot; Gilles Mentha; Timothy M Pawlik
Journal:  Surgery       Date:  2013-03-15       Impact factor: 3.982

9.  Diagnostic and Prognostic Role of 18-FDG PET/CT in the Management of Resectable Biliary Tract Cancer.

Authors:  Ka Wing Ma; Tan To Cheung; Wong Hoi She; Kenneth Siu Ho Chok; Albert Chi Yan Chan; Wing Chiu Dai; Wan Hang Chiu; Chung Mau Lo
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

10.  A genetic database can be utilized to identify potential biomarkers for biphenotypic hepatocellular carcinoma-cholangiocarcinoma.

Authors:  Shaffer R S Mok; Sachin Mohan; Navjot Grewal; Adam B Elfant; Thomas A Judge
Journal:  J Gastrointest Oncol       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.